Stay updated on Pembrolizumab + Ipilimumab vs. Placebo in NSCLC Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab + Ipilimumab vs. Placebo in NSCLC Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab + Ipilimumab vs. Placebo in NSCLC Clinical Trial page

  1. Check
    2 days ago
    Change Detected
    Summary
    The footer revision identifier changes from v3.7.2 to v3.8.0. The study record still displays a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-11-03T21:19:56.000Z thumbnail image
  2. Check
    9 days ago
    No Change Detected
  3. Check
    16 days ago
    Change Detected
    Summary
    A general NIH notice about the transition from “Artificial Intelligence” to “Super Intelligence” appears above the page, and the site revision advances from v3.7.1 to v3.7.2. The page itself continues to show a 403 error.
    Difference
    1%
    Check dated 2026-10-20T20:55:20.000Z thumbnail image
  4. Check
    30 days ago
    Change Detected
    Summary
    The site revision label changes from v3.7.0 to v3.7.1, while the study page continues to display a 403 Forbidden error.
    Difference
    0.2%
    Check dated 2026-10-06T20:46:26.000Z thumbnail image
  5. Check
    44 days ago
    Change Detected
    Summary
    The study record page now shows a 403 Forbidden error, replacing the usual content with an error message and a Home button. This indicates restricted access to the record rather than an update to the trial data.
    Difference
    17%
    Check dated 2026-09-22T22:39:02.000Z thumbnail image
  6. Check
    51 days ago
    Change Detected
    Summary
    The page now displays Revision: v3.7.0, replacing Revision: v3.6.6. This indicates a system/template update rather than changes to the study details.
    Difference
    0.0%
    Check dated 2026-09-15T20:34:18.000Z thumbnail image
  7. Check
    65 days ago
    Change Detected
    Summary
    The page's revision tag was updated from v3.6.5 to v3.6.6, indicating a small update to the page’s versioning. This change does not alter any study details, eligibility criteria, or other user-visible content.
    Difference
    0.0%
    Check dated 2026-09-01T19:15:09.000Z thumbnail image

Stay in the know with updates to Pembrolizumab + Ipilimumab vs. Placebo in NSCLC Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab + Ipilimumab vs. Placebo in NSCLC Clinical Trial page.